SetPoint Medical Announces Data Supporting Continued Clinical Development of its Bioelectronic Device for T...Read Press Release from
October 23, 2018
SetPoint Medical, headquartered in Valencia, Ca., is a privately-held clinical-stage bioelectronic medicine company dedicated to treating patients with chronic autoimmune diseases. The company is pioneering a new treatment paradigm, using electrical pulses that activate the body’s innate “Inflammatory Reflex,” for rheumatoid arthritis, Crohn’s disease and other chronic autoimmune diseases as a safe, cost-effective alternative to drugs and biologics.
Founded in 2007, SetPoint Medical started exploring the scientific principles of stimulating the vagus nerve for treatment of autoimmune diseases based on Dr. Kevin Tracey’s pioneering discovery of the Inflammatory Reflex. In 2011, SetPoint Medical initiated proof-of-concept studies for treating rheumatoid arthritis using a modified off-the-shelf vagus nerve stimulator. The successful results of this study were published in the esteemed Proceedings of the National Academy of Sciences. SetPoint Medical has raised more than $80 million to date in series A through D financing rounds with top tier VC and strategic investors.
SetPoint Medical’s revolutionary, miniaturized microregulator is currently undergoing clinical studies in the United States for rheumatoid arthritis under FDA’s Investigational Device Exemption. In parallel, the company has conducted an additional successful proof-of-concept study in Crohn’s disease as well as promising pre-clinical research in multiple sclerosis. SetPoint Medical expects to commercialize its bioelectronic medicine platform following FDA approval of its device.
For those who have a passion for developing the
next major frontier in medicine, SetPoint Medical offers a fun, fast-paced, modern work environment with excellent benefits.
INVESTIGATIONAL DEVICE DISCLAIMER: The SetPoint Medical device is an investigational device. It is currently undergoing clinical evaluation under Food and Drug Administration’s Investigational Device Exemption and is not approved for commercial use.